BIO-Europe Spring® 2017: Venneos develops next generation label-free cell analysis

April 11, 2017
Cell-based assays play a crucial role in drug discovery, toxicity testing and have the potential to contribute new insights into cellular behavior. However, many have limitations such as requiring labels or being invasive. David Wehner, managing director and co-founder of Venneos GmbH, explains to Scrip’s Mike Ward how the company is developing silicon chip-based cell adhesion noise (CAN) spectroscopy, a next generation cell analysis by focusing on electric cell properties.
Previous Video
BIO-Europe Spring® 2017: Atriva repurposes cancer drug candidates to create universal flu treatment
BIO-Europe Spring® 2017: Atriva repurposes cancer drug candidates to create universal flu treatment

Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, a 2015 startup, explains to Mike Ward, head of pharma...

Next Video
BIO-Europe Spring® 2017: Biomunex CEO on earlier deals for cancer drugs
BIO-Europe Spring® 2017: Biomunex CEO on earlier deals for cancer drugs

During the recent BIO-Europe Spring partnering conference in Barcelona, Biomunex CEO Pierre-Emmanuel Gerard...